Outlook Therapeutics Awaits FDA Feedback After Dispute Resolution

Event summary

  • Outlook Therapeutics completed a Federal Dispute Resolution (FDR) meeting with the FDA regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg).
  • The meeting follows a December 2025 Complete Response Letter (CRL) and a Type A meeting with the FDA’s Division of Ophthalmology.
  • Formal feedback from the FDA is expected in May 2026.
  • ONS-5010/LYTENAVA™ has received Marketing Authorization in the EU and UK, but remains investigational in the US.

The big picture

Outlook Therapeutics is attempting to navigate a challenging regulatory landscape for its bevacizumab ophthalmic formulation, LYTENAVA. The FDA’s CRL highlighted deficiencies that require resolution, and the FDR process represents a crucial opportunity to align on a path forward. The company’s success hinges on its ability to convince the FDA of the product’s safety and efficacy, and to secure commercial approvals in key markets, all while managing significant financial risk.

What we're watching

Regulatory Headwinds
The content of the FDA’s formal feedback in May will be critical; a rejection or significant new requirements could delay or derail US approval.
Commercial Execution
The company’s ability to secure pricing and reimbursement approvals in additional EU Member States will be a key determinant of overall revenue potential.
Financial Runway
Given the ongoing regulatory uncertainty and the need for further clinical or manufacturing data, the company’s cash reserves and ability to secure additional funding will be closely monitored.